Journal of clinical laboratory analysis · 2026
Remarkable Prolongation of Irreversible APTT and Non-Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Ke-Han, Lu Song-Song, Gao Pei-Liang, Fu Xue-Ying, Dong Gui-Ying
Аннотация
BACKGROUND: Acquired hemophilia A (AHA) is a rare hemorrhagic disease characterized by isolated prolongation of activated partial thromboplastin time (aPTT) and existence of autoantibodies against factor VIII (FVIII).
METHODS: Here, we present a patient with subcutaneous hemorrhage and remarkable prolongation of irreversible aPTT.
RESULTS: Further laboratory testing revealed reduced activity of multiple coagulation factors; this finding was subsequently identified as an artifact caused by the high-titer FVIII inhibitor, confirmed through dilution studies. Despite the high inhibitor titer and the presence of bleeding manifestations, specific anti-hemorrhagic therapy was not required for this patient. Following 6 months of immunosuppressive treatment, the patient achieved resolution of ecchymosis and maintained normal coagulation factor activity. Throughout the 12-month follow-up period, the patient ultimately died from disease progression under palliative support.
CONCLUSION: In all, this study demonstrated atypical characteristics of an AHA patient and emphasized that the treatment strategy should be guided by clinical manifestation rather than testing results solely.
METHODS: Here, we present a patient with subcutaneous hemorrhage and remarkable prolongation of irreversible aPTT.
RESULTS: Further laboratory testing revealed reduced activity of multiple coagulation factors; this finding was subsequently identified as an artifact caused by the high-titer FVIII inhibitor, confirmed through dilution studies. Despite the high inhibitor titer and the presence of bleeding manifestations, specific anti-hemorrhagic therapy was not required for this patient. Following 6 months of immunosuppressive treatment, the patient achieved resolution of ecchymosis and maintained normal coagulation factor activity. Throughout the 12-month follow-up period, the patient ultimately died from disease progression under palliative support.
CONCLUSION: In all, this study demonstrated atypical characteristics of an AHA patient and emphasized that the treatment strategy should be guided by clinical manifestation rather than testing results solely.